ArticleESMO gastrointestinal oncology2025
Article in ESMO gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06711211 (A Descriptive, Multicentre, Observational Epidemiological Study on Digestive Tumours), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Descriptive, Multicentre, Observational Epidemiological Study on Digestive Tumours
Who cites it
2 citing papers in PubMed.
- Evolving precision: Updates in targeted therapy for cholangiocarcinoma.Hepatology (Baltimore, Md.) · 2026Review
- Methylation aberrations and genomic instability synergistically drive the evolution of intrahepatic cholangiocarcinoma.Epigenomics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Antagonist of mouse double minute 2 homolog ( Materials and methods: A real-world cohort of patients diagnosed with BTC (1 January 2017 to 31 December 2022) was evaluated (RETUD NCT06711211). Next-generation sequencing (NGS) testing was carried out. Demographic and clinical characteristics, molecular profile, treatments, and effectiveness [overall response rate (ORR) and survival outcomes] were assessed. Progression-free survival (PFS), overall survival (OS), and ORR were estimated for patients receiving first-line therapy, using the Kaplan-Meier method. Descriptive analyses were used to assess demographic, clinical, and molecular features. Results: A total of 301 patients were included. Conclusions: Incidence of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.